230962-26-2

Upstream product

• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 230961-69-0 tert-butyl (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)hex-5-enoate 
• 179533-97-2 (R)-2-(2-(tert-butoxy)-2-oxoethyl)pent-4-enoic acid 
• 41604-19-7 1-bromo-3-fluoro-4-phenylbenzene 
• 230962-25-1 tert-butyl (3R,5E)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-[3-fluoro-(4-phenyl)phenyl]hex-5-enoate 

Downstream Products

• 230961-84-9 (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-[3-fluoro-(4-phenyl)phenyl]hexanoic acid 
• 230961-46-3 (2R)-N₁-[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]-2-{3-[3-fluoro-(4-phenyl)phenyl]propyl}-(N₄-3-propenyloxy)butanediamide 

Relevant academic research and scientific papers

Matrix metalloprotease inhibitors

Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors

Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1)

Structure-activity relationships are described for a series of succinyl hydroxamic acids 4a-O as potent and selective inhibitors of matrix metalloprotease-3 (stromelysin-1). Optimisation of P1′ and P3′ groups gave compound 4j (MMP-3 IC50 = 5.9 nM) which was >140-fold less potent against MMP-1 (IC50 = 51,000 nM), MMP-2 (IC50 = 1790 nM), MMP-9 (IC50 = 840 nM) and MMP-14 (IC50 = 1900 nM).